Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Alcon buys EsbaTech for $150mm in cash; $439mm earn-out

Executive Summary

Alcon has agreed to buy closely held EsbaTech AG (cancer, inflammation, and neurology therapeutics) for $150mm in cash. EsbaTech shareholders may also receive up to $439mm in earn-outs based on the achievement of R&D milestones.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Earnout
    • Full Acquisition
    • Payment Includes Cash
    • Acquisition of Private Biotech

Related Companies

Advertisement
UsernamePublicRestriction

Register